Patents by Inventor Jamie L. Harden

Jamie L. Harden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IRAK4 Inhibitors and Topical Uses Thereof
    Publication number: 20230390265
    Abstract: This invention is directed to compositions including IRAK4 inhibitors useful for the treatment of dermatological disorders or conditions characterized by inflammation. This invention is also directed to methods for treating the dermatological disorders or conditions.
    Type: Application
    Filed: June 29, 2021
    Publication date: December 7, 2023
    Inventors: Jamie L. Harden, Delphine Imbert
  • ROR gamma t Inhibitors and Topical Uses Thereof
    Publication number: 20230321124
    Abstract: The present disclosure is directed to use of ROR?t inhibitors in the treatment of autoimmune disorders, e.g., autoimmune disorders of the skin. This invention is also directed to pharmaceutical compositions comprising an ROR?t inhibitor and a pharmaceutically acceptable carrier for topical administration.
    Type: Application
    Filed: June 29, 2021
    Publication date: October 12, 2023
    Inventors: Jamie L. Harden, Delphine Imbert
  • Topical Compositions Comprising IRAK4 Inhibitors for Use in Treating Dermatological Conditions Characterised by Inflammation
    Publication number: 20230125380
    Abstract: This disclosure is directed to use of IRAK4 inhibitors in the treatment of dermatological disorders or conditions characterized by inflammation This disclosure is also directed to pharmaceutical compositions comprising an IRAK4 inhibitor and a pharmaceutically acceptable carrier for topical administration
    Type: Application
    Filed: November 5, 2020
    Publication date: April 27, 2023
    Inventors: Jamie L. Harden, Hans E.J. Hofland
  • ROR Gamma T Inhibitors and Topical Uses Thereof
    Publication number: 20220409643
    Abstract: The present disclosure is directed to use of ROR?t inhibitors in the treatment of autoimmune disorders, e.g., autoimmune disorders of the skin. This disclosure is also directed to pharmaceutical compositions comprising an ROR?t inhibitor and a pharmaceutically acceptable carrier for topical administration.
    Type: Application
    Filed: November 5, 2020
    Publication date: December 29, 2022
    Inventors: Jamie L. Harden, Hans E.J. Hofland